
Last update at 2026-03-11T17:56:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
1 Cash-Heavy Stock That Stand Out and 2 to Question
Fri 09 May 25, 04:34 AMLeMaitre Vascular First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Sat 03 May 25, 12:21 PMWhy LeMaitre (LMAT) Shares Are Sliding Today
Fri 02 May 25, 07:42 PMLeMaitre’s (NASDAQ:LMAT) Q1: Beats On Revenue, Guides for Strong Full-Year Sales
Thu 01 May 25, 09:43 PMLeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
Thu 01 May 25, 09:20 PMLeMaitre Q1 2025 Financial Results
Thu 01 May 25, 08:05 PMEarnings To Watch: LeMaitre (LMAT) Reports Q1 Results Tomorrow
Wed 30 Apr 25, 07:12 AM1 Profitable Stock with Impressive Fundamentals and 2 to Steer Clear Of
Mon 28 Apr 25, 01:08 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 27.49M | 34.29M | 27.36M | 21.68M | 28.44M |
| Minority interest | - | - | - | - | - |
| Net income | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
| Selling general administrative | 28.75M | 25.50M | 22.50M | 19.05M | 17.69M |
| Selling and marketing expenses | 32.92M | 27.66M | 23.70M | 30.34M | 27.32M |
| Gross profit | 104.90M | 101.38M | 84.62M | 79.85M | 73.94M |
| Reconciled depreciation | 9.43M | 11.07M | 8.39M | 5.42M | 4.32M |
| Ebit | 21.16M | 25.55M | 19.80M | 15.77M | 8.94M |
| Ebitda | 30.60M | 36.62M | 28.20M | 21.18M | 13.26M |
| Depreciation and amortization | 9.43M | 11.07M | 8.39M | 5.42M | 4.32M |
| Non operating income net other | 0.66M | 0.08M | -0.12200M | 0.50M | 0.24M |
| Operating income | 21.16M | 25.55M | 19.80M | 15.77M | 28.21M |
| Other operating expenses | 131.72M | 118.00M | 101.05M | 96.05M | 84.83M |
| Interest expense | 0.99M | 2.22M | 1.31M | 5.91M | 0.00200M |
| Tax provision | 6.85M | 7.38M | 6.14M | 3.75M | 5.50M |
| Interest income | 0.99M | 0.20M | 0.21M | 0.70M | 0.63M |
| Net interest income | 0.99M | -2.02200M | -1.31000M | 0.70M | 0.63M |
| Extraordinary items | - | - | - | - | 0.40M |
| Non recurring | 3.11M | - | -0.47000M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 6.85M | 7.38M | 6.14M | 3.75M | 5.50M |
| Total revenue | 161.65M | 154.42M | 129.37M | 117.23M | 105.57M |
| Total operating expenses | 74.96M | 64.96M | 56.30M | 58.67M | 53.20M |
| Cost of revenue | 56.76M | 53.04M | 44.75M | 37.38M | 31.63M |
| Total other income expense net | 6.33M | 8.73M | 7.55M | 5.91M | 7.71M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
| Net income applicable to common shares | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 346.78M | 310.48M | 292.80M | 252.81M | 188.34M |
| Intangible assets | 41.71M | 46.53M | 52.71M | 58.91M | 23.19M |
| Earning assets | - | - | - | - | - |
| Other current assets | 6.38M | 6.73M | 4.19M | 2.62M | 3.31M |
| Total liab | 48.88M | 42.27M | 38.65M | 80.24M | 40.20M |
| Total stockholder equity | 297.90M | 268.20M | 254.15M | 172.57M | 148.14M |
| Deferred long term liab | - | - | 0.07M | 0.70M | 1.18M |
| Other current liab | 23.28M | 20.54M | 1.27M | 0.77M | 2.48M |
| Common stock | 0.24M | 0.24M | 0.23M | 0.22M | 0.22M |
| Capital stock | 0.24M | 0.24M | 0.23M | 0.22M | 0.22M |
| Retained earnings | 115.43M | 97.77M | 88.12M | 70.55M | 57.03M |
| Other liab | - | 2.24M | 2.77M | 4.77M | 5.39M |
| Good will | 65.94M | 65.94M | 65.94M | 65.94M | 41.66M |
| Other assets | - | 2.74M | 2.13M | 18.45M | 1.34M |
| Cash | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 29.88M | 25.33M | 21.81M | 25.14M | 20.86M |
| Current deferred revenue | 0.39M | - | 16.33M | 17.52M | 14.02M |
| Net debt | -5.17400M | -2.53800M | 2.08M | 28.01M | 3.93M |
| Short term debt | 2.47M | 1.89M | 1.87M | 4.45M | 1.76M |
| Short long term debt | - | - | - | 2.50M | - |
| Short long term debt total | 19.09M | 16.60M | 15.94M | 54.78M | 15.71M |
| Other stockholder equity | 186.86M | 176.22M | 169.23M | 103.32M | 94.90M |
| Property plant equipment | - | 17.90M | 32.13M | 15.04M | 14.85M |
| Total current assets | 188.85M | 161.73M | 139.88M | 94.26M | 92.09M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 155.73M | 135.50M | 113.67M | 108.19M |
| Short term investments | 80.81M | 63.56M | 56.10M | 0.21M | 20.89M |
| Net receivables | 25.06M | 22.04M | 19.63M | 19.55M | 16.57M |
| Long term debt | - | - | - | 35.53M | - |
| Inventory | 52.33M | 50.27M | 46.10M | 45.12M | 39.53M |
| Accounts payable | 3.73M | 2.90M | 2.34M | 2.39M | 2.60M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.62500M | -6.03100M | -3.43500M | -1.52500M | -4.00700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.24M | 0.23M | 0.22M | 0.22M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 97.77M | 88.12M | 70.55M | 57.03M |
| Treasury stock | - | -13.04600M | -12.40400M | -11.60200M | -11.03200M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9.49M | 0.99M | 0.57M | 0.91M | 0.26M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 157.93M | 148.74M | 152.92M | 158.55M | 96.25M |
| Capital lease obligations | 19.09M | 16.60M | 15.94M | 16.75M | 15.71M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -22.85600M | -8.00000M | -56.19400M | 20.70M | 0.90M |
| Change to liabilities | - | 0.65M | -1.73400M | 4.32M | -0.59600M |
| Total cashflows from investing activities | - | -10.37100M | -61.07600M | -52.89100M | -24.10000M |
| Net borrowings | - | - | -39.00000M | 37.25M | 39.00M |
| Total cash from financing activities | -7.13100M | -9.23400M | 13.70M | 32.16M | -4.62200M |
| Change to operating activities | - | -3.09600M | -1.92700M | 0.09M | -0.65400M |
| Net income | 30.11M | 20.64M | 26.91M | 21.22M | 17.93M |
| Change in cash | 5.13M | 5.28M | -12.90900M | 14.98M | -14.53200M |
| Begin period cash flow | 19.13M | 13.86M | 26.76M | 11.79M | 26.32M |
| End period cash flow | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M |
| Total cash from operating activities | 36.75M | 25.38M | 35.10M | 34.80M | 14.18M |
| Issuance of capital stock | 6.86M | 3.47M | 63.24M | 5.97M | 4.86M |
| Depreciation | 9.52M | 9.43M | 11.07M | 8.39M | 5.42M |
| Other cashflows from investing activities | - | 0.86M | - | -70.60400M | -21.24000M |
| Dividends paid | 12.45M | 10.99M | 9.34M | 7.70M | 6.74M |
| Change to inventory | -9.79400M | -7.41800M | -5.48500M | -2.60900M | -11.33500M |
| Change to account receivables | -3.13500M | -3.53300M | -0.81800M | -0.93900M | -1.30100M |
| Sale purchase of stock | -0.85300M | -0.64200M | -0.80200M | -0.57000M | -0.68300M |
| Other cashflows from financing activities | 7.13M | -1.07000M | -0.40100M | 60.45M | -2.05900M |
| Change to netincome | - | 8.71M | 7.09M | 4.32M | 4.71M |
| Capital expenditures | 7.26M | 3.23M | 4.88M | 2.98M | 3.76M |
| Change receivables | - | -3.53300M | -0.81800M | -0.93900M | -1.30100M |
| Cash flows other operating | - | -10.51400M | -7.41200M | -2.52000M | -11.98900M |
| Exchange rate changes | - | - | - | - | 0.01M |
| Cash and cash equivalents changes | - | 5.77M | -12.27200M | 14.06M | -14.53200M |
| Change in working capital | -11.25400M | -13.40200M | -9.96400M | 0.86M | -13.88600M |
| Stock based compensation | 5.32M | 4.17M | 3.48M | 3.02M | 2.64M |
| Other non cash items | 2.28M | 4.72M | 3.53M | 1.63M | 1.25M |
| Free cash flow | 29.49M | 22.15M | 30.22M | 31.82M | 10.42M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LMAT LeMaitre Vascular Inc |
-1.9301 1.77% | 107.27 | 52.74 | 38.76 | 7.46 | 4.85 | 7.02 | 27.72 |
| ISRG Intuitive Surgical Inc |
5.12 1.05% | 490.96 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.64 0.52% | 121.86 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 243.04 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.85 1.13% | 162.03 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
63 Second Avenue, Burlington, MA, United States, 01803
| Name | Title | Year Born |
|---|---|---|
| Mr. George W. LeMaitre | Chairman & CEO | 1965 |
| Mr. David B. Roberts | Pres & Director | 1964 |
| Mr. Joseph P. Pellegrino Jr. | CFO, Treasurer, Sec. & Director | 1965 |
| Mr. Trent G. Kamke | Sr. VP of Operations | 1971 |
| Dr. George D. LeMaitre | Founder and Chairman of Scientific Advisory Board | 1934 |
| Ms. Laurie A. Churchill | Sr. VP & Gen. Counsel | 1971 |
| Ms. Kimberly L. Cieslak | VP of Marketing | 1973 |
| Mr. Daniel J. Mumford | Director of HR | 1982 |
| Mr. Andrew Hodgkinson | Sr. VP of Clinical, Regulatory & Quality Affairs | 1976 |
| Mr. Stephane Maier | Sr. VP of EMEA Operations | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.